艾沙奇珠单抗在709例真实世界中轴性脊柱关节炎与银屑病关节炎患者的有效性:一项全国性队列研究
基于丹麦全国DANBIO注册的观察性队列研究纳入709例(axSpA 231例、PsA 478例)起始艾沙奇珠单抗治疗的患者,多数有生物制剂使用史。axSpA与PsA的24个月留存率分别为40%与51%,既往使用过其他IL-17i与撤药风险升高相关。作者认为艾沙奇珠单抗对多种b/tsDMARD失败的患者是可行选择。
要点
- axSpA 24个月留存率40%,PsA为51%。
- 既往其他IL-17i治疗者撤药风险升高(axSpA aHR 1.48,PsA aHR 2.38)。
- 6个月时axSpA的ASDAS-LDA为24%、缓解5%;PsA的DAPSA28-LDA为43%、缓解10%。
核心结论
- 在这项全国性观察性研究中,艾沙奇珠单抗主要用于已失败多种b/tsDMARD(包括其他IL-17i)的患者,axSpA留存率略低于PsA;两种疾病中既往IL-17i治疗均与撤药风险升高相关,但相对较高的留存率和所有疾病活动度指标的改善提示艾沙奇珠单抗对多种b/tsDMARD失败的患者是可行选择。
研究设计与样本
- 基于丹麦全国质量注册DANBIO数据的观察性队列研究,纳入2017年至2024年间起始艾沙奇珠单抗(一种IL-17i)的axSpA和PsA患者,共709例(axSpA 231例,PsA 478例)。
主要发现
- 多数患者有生物制剂使用史(axSpA 97%,PsA 91%)。
- 6、12、24个月留存率axSpA分别为69%(95%CI 63;76)、53%(46;60)、40%(33;49),PsA分别为75%(71;79)、63%(58;67)、51%(46;57)。
- 既往使用过其他IL-17i者(axSpA 36%,PsA 34%)撤药风险升高(aHR:axSpA 1.48(1.01;2.17),PsA 2.38(1.79;3.15))。
- 吸烟、影像学状态(axSpA)或合并甲氨蝶呤(PsA)与撤药无关。
- 6个月后axSpA中24%达ASDAS-LDA、5%达ASDAS缓解;PsA中43%达DAPSA28-LDA、10%达DAPSA28缓解。
关键数值与推荐
- axSpA低疾病活动度定义为ASDAS<2.1、缓解定义为ASDAS<1.3;PsA低疾病活动度定义为DAPSA28≤14、缓解定义为DAPSA28≤4。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To explore real-world effectiveness of ixekizumab in Danish patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA). METHODS: Observational cohort study based on data from the Danish nationwide quality registry, DANBIO. Patients with axSpA and PsA initiating ixekizumab (an interleukin 17 inhibitor (IL-17i)) between 2017 and 2024 were included. Outcomes were 6-, 12- and 24-month retention rates and low disease activity (LDA)/remission after 6 months (axSpA: Axial Spondyloarthritis Disease Activity Score (ASDAS) <2.1/<1.3, PsA: Disease Activity index for Psoriatic Arthritis (DAPSA28) ≤14/≤4, respectively). Clinical factors associated with retention were explored (multivariable Cox regression analyses with adjusted HRs (aHRs)). RESULTS: 709 patients were included (axSpA: 231, PsA: 478). Most patients were bio-experienced (axSpA: 97%, PsA: 91%). The 6-, 12- and 24-month retention rates were for axSpA: 69% (95% CI 63; 76), 53% (46; 60) and 40% (33; 49); for PsA: 75% (71; 79), 63% (58; 67) and 51% (46; 57), respectively. Patients previously treated with another IL-17i (axSpA 36%, PsA 34%) had an increased risk of withdrawal (aHR: axSpA 1.48 (1.01; 2.17), PsA 2.38 (1.79; 3.15)). Smoking, radiographic status (axSpA) or concomitant methotrexate (PsA) were not associated with withdrawal. After 6 months, 24% of axSpA patients had ASDAS-LDA, and 5% were in ASDAS-remission. For PsA, DAPSA28-LDA was achieved in 43% and DAPSA28-remission in 10%, respectively. CONCLUSION: In this nationwide observational study, ixekizumab was primarily prescribed in patients who had failed multiple biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), including other IL-17i. Retention rates were somewhat lower for axSpA than for PsA. For both axSpA and PsA, prior IL-17i treatment was associated with an increased risk of withdrawal, yet the relatively high retention rate and improvement in all disease activity outcomes suggest ixekizumab as a viable option for patients with multiple b/tsDMARD failures.
引用
- Jensen KY, Grøn KL, Hetland ML, et al. Effectiveness of ixekizumab in 709 real-world patients with axial spondyloarthritis and psoriatic arthritis: a nationwide cohort study. RMD Open. 2025. PMID: 40701624. doi:10.1136/rmdopen-2025-005806
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。